Fig. 5
From: A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation
Knockdown of VMAT-2 results in decreased process elongation. (A, B) N1E-115 cells were transfected with plasmids encoding Cas13 with control gRNA (gControl) or VMAT-2 one (gVMAT-2). Following the induction of differentiation, cells were cultured for 3 days. The morphology of the cells at day 0 is also depicted in the diagram. Cells with processes were counted and graphically represented (** p < 0.01; n = 10 fields). (C, D) The lysates of the respective cells were used for immunoblotting with antibodies against GAP43, Tau, and control actin. The expression levels of GAP43 and Tau were normalized to those of actin and graphically represented (** p < 0.01; n = 3 blots).
